Addyi (Flibanserin) Dosing in Renal Impairment
Evidence-based guide to flibanserin (Addyi) dosing in patients with renal impairment, including pharmacokinetic data, FDA labeling, clinical trial evidence, and practical prescribing considerations.
Flibanserin
36 source-based articles maintained by the HealthRX.com Editorial Team.
36articles
7topic areas covered
May 25, 2026latest review
Flibanserin library
Showing 36 of 36 clinical reviews.
Addyi (Flibanserin) During Pregnancy and Lactation: What the Evidence Actually Shows
Is flibanserin (Addyi) safe during pregnancy or breastfeeding? A clinician-grade review of FDA labeling, animal reproductive data, lactation pharmacokinetics, and practical guidance for HSDD management in the peripartum period.
Addyi (Flibanserin) Food & Supplement Interactions: What to Avoid and Why
A guide to flibanserin (Addyi) food and supplement interactions, including alcohol, grapefruit, CYP3A4 inhibitors, and herbal products that alter drug levels.
Addyi (Flibanserin) in Special Populations: Transplant, HIV, Hepatic Impairment, and Beyond
Evidence-based guide to flibanserin use in special populations including organ transplant recipients, women living with HIV, those with hepatic impairment, and other complex clinical scenarios.
Addyi (Flibanserin) Missed-Dose Protocol: What to Do and When to Resume
Evidence-based guidance on what to do if you miss a dose of flibanserin (Addyi), including timing rules, safety precautions, and how skipping doses affects efficacy.
Addyi (Flibanserin) Monitoring for Adults (30 to 49): What to Track and When
A clinical guide to monitoring flibanserin (Addyi) in premenopausal adults aged 30 to 49, covering liver function, blood pressure, alcohol screening, CNS depression risk, and CYP3A4 drug interactions.
Addyi (Flibanserin) Overdose and Accidental Excess Dose: What to Know and How to Respond
Clinical guide to flibanserin (Addyi) overdose management, including symptoms of excess dosing, pharmacologic mechanisms, emergency treatment protocols, and prevention strategies backed by FDA labeling and trial data.
Addyi (Flibanserin) Regulatory Status: US, EU, Canada, and UK
A clinician-level review of flibanserin (Addyi) regulatory approvals and rejections across the US, EU, Canada, and UK, including trial data, REMS requirements, and prescribing restrictions.
Addyi (Flibanserin) Safety in Adults Aged 30 to 49: What the Trials Actually Show
A clinical review of flibanserin (Addyi) safety data for premenopausal women aged 30 to 49, covering side effects, drug interactions, alcohol warnings, and monitoring recommendations.
Addyi (Flibanserin) Safety in Young Adults Ages 18 to 29: What the Evidence Actually Shows
A guide to flibanserin (Addyi) safety for women ages 18 to 29, covering the alcohol interaction, CNS effects, fertility considerations, and the BEGONIA trial data.
Addyi (Flibanserin) Safety Signals and FDA Actions: A Clinical Timeline
A detailed review of flibanserin (Addyi) safety signals, FDA rejections, REMS requirements, alcohol interaction warnings, and post-marketing surveillance data for HSDD treatment.
Addyi (Flibanserin): History, Development, and How It Works
A clinical history of flibanserin (Addyi), from its origins as a failed antidepressant to its FDA approval for hypoactive sexual desire disorder in premenopausal women, including mechanism of action, key trials, and regulatory timeline.
Addyi Adult (30-49) Dosing: Flibanserin Dose, Timing, and Safety Guide
Complete clinical guide to flibanserin (Addyi) dosing for adult women aged 30-49, including the standard 100 mg bedtime dose, alcohol restrictions, drug interactions, and what to expect from treatment.
Addyi Cost vs. Alternatives: Flibanserin Pricing, Generic Options, and Comparable HSDD Treatments
A clinical breakdown of flibanserin (Addyi) pricing, generic availability, and how it compares in cost and efficacy to bremelanotide (Vyleesi) and off-label alternatives for HSDD.
Addyi Future Formulations & Pipeline: What's Next for Flibanserin
A clinical review of flibanserin (Addyi) pipeline developments, new delivery systems under investigation, and the future of HSDD pharmacotherapy for premenopausal women.
Addyi Geriatric (65+) Safety: What Older Women and Their Doctors Need to Know
A guide to flibanserin (Addyi) safety in women aged 65 and older, covering falls risk, drug interactions, renal function, and deprescribing considerations backed by clinical evidence.
Addyi Manufacturing, Supply & Shortage History
A clinical deep-dive into flibanserin (Addyi) manufacturing, supply chain history, shortage events, mechanism of action, and what prescribers and patients need to know in 2024.
Addyi Mechanism of Action: The Full Pathway Explained
A physician-level breakdown of how flibanserin (Addyi) works, covering its serotonin, dopamine, and norepinephrine receptor pharmacology, the BEGONIA trial data, and what the neuroscience means for clinical practice.
Addyi Monitoring Schedule: Labs, Exams & Follow-Up Timeline for Flibanserin
Evidence-based monitoring schedule for flibanserin (Addyi), including baseline labs, liver function testing, blood pressure checks, and follow-up exam intervals.
Addyi Patent & Generic Timeline: When Will Generic Flibanserin Be Available?
A clinical breakdown of flibanserin (Addyi) patent status, regulatory exclusivity, generic approval pathway, and projected availability dates for generic versions.
Addyi Pharmacokinetics (ADME): Absorption, Distribution, Metabolism, and Elimination of Flibanserin
Complete pharmacokinetic profile of flibanserin (Addyi) including absorption, distribution, CYP3A4 metabolism, elimination half-life, food effects, and clinical implications for HSDD treatment.
Addyi Real-World Evidence: What Registries and Post-Market Data Show About Flibanserin
A clinical review of flibanserin (Addyi) real-world evidence from registries, post-market surveillance, and observational studies, including mechanism of action and effectiveness outside clinical trials.
Addyi Storage, Stability & Shelf Life: What You Need to Know About Flibanserin
Complete guide to flibanserin (Addyi) storage conditions, shelf life, stability data, and mechanism of action. with FDA and PubMed citations.
Does Aetna (CVS Health) Cover Addyi (Flibanserin)?
A complete guide to Aetna CVS Health coverage for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, appeal strategy, and cost-saving options for premenopausal women with HSDD.
Does Anthem (Elevance Health) Cover Addyi (Flibanserin)?
A clinical and coverage guide to Anthem (Elevance Health) prior authorization, step therapy, formulary tier, and appeal pathways for Addyi (flibanserin) for HSDD in premenopausal women.
Does Humana Cover Addyi (Flibanserin)? Coverage, Prior Auth, and Appeals Explained
A clinical guide to Humana coverage of Addyi (flibanserin) for HSDD: formulary tiers, prior authorization requirements, step therapy, appeal pathways, and out-of-pocket cost options.
Does Kaiser Permanente Cover Addyi (Flibanserin)?
A detailed guide to Kaiser Permanente's coverage policy, prior-authorization requirements, formulary tier, step-therapy rules, and appeal process for Addyi (flibanserin) for HSDD.
Does Medicare Advantage (Any Carrier) Cover Addyi (Flibanserin)?
A detailed look at Medicare Advantage coverage policies for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary status, appeal rights, and cash-pay alternatives for premenopausal women with HSDD.
Does State Medicaid Cover Addyi (Flibanserin)?
A state-by-state guide to Medicaid coverage of flibanserin (Addyi) for HSDD: formulary status, prior authorization criteria, step therapy requirements, appeal rights, and cost alternatives.
Does TRICARE Cover Addyi (Flibanserin)? Coverage, Prior Auth, and Appeals Explained
Find out whether TRICARE covers Addyi (flibanserin) for HSDD, what prior-authorization criteria apply, how step therapy works, and exactly how to appeal a denial. prepared by the HealthRX.com Editorial Team.
Does UnitedHealthcare Cover Addyi (Flibanserin)?
A guide to UnitedHealthcare coverage for Addyi (flibanserin), including prior authorization criteria, step therapy requirements, formulary tier placement, appeals, and cost-saving strategies for HSDD treatment.
Flibanserin (Addyi) Complete Drug-Drug Interaction Profile
A clinician-grade guide to every major flibanserin (Addyi) drug interaction, including CYP3A4 inhibitors, alcohol, CNS depressants, hormonal contraceptives, and P-gp substrates, with FDA and PubMed citations.
Flibanserin (Addyi) Dosing in Hepatic Impairment: Why It Is Contraindicated
Flibanserin is contraindicated in all degrees of hepatic impairment due to a 4.5-fold increase in drug exposure. Learn the pharmacokinetic data, FDA warnings, and clinical alternatives.
Flibanserin (Addyi) Off-Label Uses: Evidence Levels for Every Indication
A clinician-grade review of flibanserin off-label uses beyond FDA-approved HSDD in premenopausal women, with trial data, evidence grading, and safety considerations for each indication.
How to Safely Stop Flibanserin (Addyi): Discontinuation Protocol
Evidence-based guide to safely discontinuing flibanserin (Addyi), including taper considerations, timeline expectations, and what to discuss with your prescriber before stopping.
Switching From or To Flibanserin (Addyi): Protocols, Timelines, and What to Expect
Evidence-based guide to switching from flibanserin (Addyi) to bremelanotide (Vyleesi) or other HSDD treatments, including washout periods, dose adjustments, and clinical monitoring.